Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/16375
DC FieldValueLanguage
dc.contributor.authorValgimigli, Marcoen_US
dc.contributor.authorCosta, Francescoen_US
dc.contributor.authorByrne, Roberten_US
dc.contributor.authorHaude, Michaelen_US
dc.contributor.authorBaumbach, Andreasen_US
dc.contributor.authorWindecker, Stephanen_US
dc.contributor.authorVavlukis, Marijaen_US
dc.contributor.authorBoshev, Marijanen_US
dc.date.accessioned2022-02-03T14:18:43Z-
dc.date.available2022-02-03T14:18:43Z-
dc.date.issued2015-05-01-
dc.identifier.citationValgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S, Aaroe J, Biasco L, De Backer O, Hansen PR, Kristensen SD. Dual antiplatelet therapy duration after coronary stenting in clinical practice: Results of an EAPCI survey. EuroIntervention. 2015;11(1):68-74.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12188/16375-
dc.descriptionAims: Our aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) concerning opinion on the evidence relating to dual antiplatelet therapy (DAPT) duration after coronary stenting. Methods and results: Results from three randomised clinical trials were scheduled to be presented at the American Heart Association Scientific Sessions 2014 (AHA 2014). A web-based survey was distributed to all individuals registered in the EuroIntervention mailing list (n=15,200) both before and after AHA 2014. A total of 1,134 physicians responded to the first (i.e., before AHA 2014) and 542 to the second (i.e., after AHA 2014) survey. The majority of respondents interpreted trial results consistent with a substantial equipoise regarding the benefits and risks of an extended versus a standard DAPT strategy. Two respondents out of ten believed extended DAPT should be implemented in selected patients. After AHA 2014, 46.1% of participants expressed uncertainty about the available evidence on DAPT duration, and 40.0% the need for clinical guidance. Conclusions: This EAPCI survey highlights considerable uncertainty within the medical community with regard to the optimal duration of DAPT after coronary stenting in the light of recent reported trial results. Updated recommendations for practising physicians to guide treatment decisions in routine clinical practice should be provided by international societies. © Europa Digital & Publishing 2015. All rights reserved.en_US
dc.description.abstractOur aim was to report on a survey initiated by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) concerning opinion on the evidence relating to dual antiplatelet therapy (DAPT) duration after coronary stenting.en_US
dc.language.isoenen_US
dc.publisherEuroPCRen_US
dc.relationEAPCI surveyen_US
dc.relation.ispartofEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiologyen_US
dc.subjectDrug Administration Scheduleen_US
dc.subjectDrug Therapyen_US
dc.subjectCombinationen_US
dc.subjectEvidence-Based Medicineen_US
dc.subjectSurveysen_US
dc.subjectPercutaneous Coronary Interventionen_US
dc.subjectPlatelet Aggregation Inhibitorsen_US
dc.subjectTreatmenten_US
dc.subjectOutcomeen_US
dc.titleDual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI surveyen_US
dc.typeArticleen_US
dc.identifier.doi10.4244/EIJV11I1A11-
dc.identifier.volume11-
dc.identifier.issue1-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Faculty of Medicine: Journal Articles
Show simple item record

Page view(s)

103
checked on Oct 10, 2024

Download(s)

36
checked on Oct 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.